ÂÜÀòÂÒÂ×

Daniel Lazzari is the Vice President of Finance at Tevard Biosciences. Daniel has over fifteen years of experience in the pharmaceutical and biotech industry.

Lazzari began their career at Genzyme Corporation where they worked for three years as the Associate Director of Finance. Daniel then moved to Ironwood Pharmaceuticals and worked as the Commercial Business Partner for Financial Planning and Analysis for two years. In this role, they were responsible for providing financial analysis to support the commercial team and developing long-range forecast drivers and assumptions.

In 2013, Lazzari joined Sanofi Genzyme as the Head of Business Intelligence and US Leukine Commercial Lead. In this role, they were responsible for leading the financial due diligence on the $400M acquisition of Leukine. Daniel also managed the company integration post-acquisition.

In 2015, Lazzari joined Spero Therapeutics as the Head of Commercial Finance. In this role, they were responsible for developing, budgeting, and hiring the Commercial Finance team. Daniel also advised the Executive Team on pricing governance and long-range forecasting.

Lazzari joined Tevard Biosciences in 2016 as the Vice President of Finance. In this role, they are responsible for leading the financial planning and analysis for the company.

Daniel Lazzari has a Master of Business Administration (MBA) from the Massachusetts Institute of Technology (2013 - 2015) and a degree from Northeastern University (1995 - 2000).